Sign In
Buy CRNX
$33.09
+0.480 (+1.47%)
At Close: Jun 03, 2026
Crinetics Pharmaceuticals Inc:
Crinetics Pharma's paltusotine shows encouraging action in mid-stage study
09:04pm, Monday, 06'th Apr 2020
Crinetics Pharmaceuticals (NASDAQ:CRNX) reports positive interim data from a Phase 2 clinical trial, ACROBAT EDGE, evaluating oral paltusotine (CRN00808) in patients with acromegaly, a rare disorder i
Data from initial patients who have completed the ongoing open label Edge trial show that IGF-1 levels were maintained after 13 weeks of treatment when patients were switched to once daily oral paltus
Data from initial patients who have completed the ongoing open label Edge trial show that IGF-1 levels were maintained after 13 weeks of treatment when...
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Rating Reaffirmed by HC Wainwright
07:08am, Saturday, 04'th Apr 2020
Crinetics Pharmaceuticals (NASDAQ:CRNX)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Friday, TipRanks reports. They currently have a $35.00 price objective
Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX), Crinetics Pharmaceuticals (CRNX) and Collplant Holdings (CLGN)
11:11am, Friday, 03'rd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX), Crinetics Pharmaceuticals (CRNX) and
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX
Citigroup Inc. Grows Holdings in Crinetics Pharmaceuticals Inc (NASDAQ:CRNX)
09:52am, Thursday, 02'nd Apr 2020
Citigroup Inc. grew its holdings in Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) by 90.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchang
Zacks: Analysts Expect Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) to Post -$0.63 Earnings Per Share
09:47am, Sunday, 29'th Mar 2020
Brokerages expect that Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) will report earnings of ($0.63) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estim
Crinetics Pharmaceuticals (CRNX) - Research Analysts' Recent Ratings Changes
10:26am, Monday, 23'rd Mar 2020
Crinetics Pharmaceuticals (NASDAQ: CRNX) recently received a number of ratings updates from brokerages and research firms: 3/18/2020 – Crinetics Pharmaceuticals had its “overweight” rating reaff
Crinetics Pharmaceuticals (NASDAQ:CRNX) Earns "Overweight" Rating from Cantor Fitzgerald
05:10am, Sunday, 22'nd Mar 2020
Cantor Fitzgerald restated their overweight rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) in a research report released on Wednesday, Zacks.com reports. A number of other equities analys
Barclays PLC Buys 5,215 Shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX)
09:44am, Wednesday, 18'th Mar 2020
Barclays PLC boosted its stake in shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) by 87.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commiss
Zacks Investment Research Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Buy
08:54am, Monday, 16'th Mar 2020
Zacks Investment Research upgraded shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a hold rating to a buy rating in a report published on Thursday morning, Zacks.com reports. The firm currently
Crinetics Pharmaceuticals (NASDAQ:CRNX) Given "Buy" Rating at HC Wainwright
07:28am, Sunday, 15'th Mar 2020
HC Wainwright reiterated their buy rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) in a research report released on Wednesday, Zacks.com reports. Several other research firms have also iss
Crinetics Pharmaceuticals Inc Forecasted to Post FY2024 Earnings of ($4.80) Per Share (NASDAQ:CRNX)
08:26am, Saturday, 14'th Mar 2020
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) – Analysts at Piper Sandler issued their FY2024 earnings per share (EPS) estimates for Crinetics Pharmaceuticals in a research report issued on Monday, Ma
